cdifffoundation.org
FDA Grants Qualified Infectious Disease Product and Fast Track Designation To Morphochem’s IV Antibacterial Product Candidate MCB3837 To Treat C.diff. Infections
Morphochem is a clinical-stage pharmaceutical company, announced July 25, 2016 that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous (IV) antibacterial product ca…